Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our high-tech, dedicated method is applied to construct targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
P55291

UPID:
CAD15_HUMAN

ALTERNATIVE NAMES:
Cadherin-14; Muscle cadherin

ALTERNATIVE UPACC:
P55291

BACKGROUND:
Cadherin-15, known alternatively as Muscle cadherin or Cadherin-14, is integral to cell adhesion processes, facilitating the organization of heterogeneous cell types through calcium-dependent homophilic interactions. Its critical role in the myogenic program, triggering muscle differentiation, positions it as a key player in tissue formation and maintenance.

THERAPEUTIC SIGNIFICANCE:
The association of Cadherin-15 with Intellectual developmental disorder, autosomal dominant 3, highlights its therapeutic potential. Exploring the functions of Cadherin-15 could lead to groundbreaking therapeutic strategies, providing new avenues for treating or managing this developmental disorder.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.